We are live on ! Find out more
KYNB

Kyntra Bio

32 hedge funds and large institutions have $7.01M invested in Kyntra Bio in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,257% more call options, than puts

Call options by funds: $655K | Put options by funds: $7K

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

3.13% less ownership

Funds ownership: 28.7%25.57% (-3.1%)

6% less funds holding

Funds holding: 3432 (-2)

31% less capital invested

Capital invested by funds: $10.2M → $7.01M (-$3.18M)

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

Holders
32
Holders Change
-2
Holders Change %
-5.88%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
5
Reduced
8
Closed
8
Calls
$655K
Puts
$7K
Net Calls
+$648K
Net Calls Change
-$1.04M
Name Holding Trade Value Shares
Change
Change in
Stake
Carson Wealth (CWM LLC)
26
Carson Wealth (CWM LLC)
Nebraska
$176
JP Morgan Chase
27
JP Morgan Chase
New York
$78
CWMS
28
CFG Wealth Management Services
Indiana
$20
DB
29
Danske Bank
Denmark
$7
US Bancorp
30
US Bancorp
Minnesota
$7
Citigroup
31
Citigroup
New York
$7 +$8 +1 New
Marshall Wace
32
Marshall Wace
United Kingdom
-$285K -32,502 Closed
DS
33
DRW Securities
Illinois
-$267K -30,420 Closed
Two Sigma Advisers
34
Two Sigma Advisers
New York
-$200K -22,809 Closed
Corient Private Wealth
35
Corient Private Wealth
Florida
-$176K -20,026 Closed
Citadel Advisors
36
Citadel Advisors
Florida
-$147K -16,756 Closed
Northern Trust
37
Northern Trust
Illinois
-$113K -12,852 Closed
Squarepoint
38
Squarepoint
New York
-$107K -12,186 Closed
Bank of America
39
Bank of America
North Carolina
-$5.22K -595 Closed

KYNB Hedge Fund Activity: Q1 2026 in Review

32 of the 8,161 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q1 2026, worth a combined $7.01M — down 31% from $10.2M a quarter earlier.

Fund positioning in KYNB was balanced in Q1 2026: 8 funds opened new positions, 8 closed out, 5 added to existing stakes and 8 trimmed.

The largest buyer was Birchview Capital, opening a new position worth an estimated $177K. The largest seller was Marshall Wace, exiting entirely with an estimated $285K sold.

  • 32 institutional investors held Kyntra Bio (KYNB) as of Q1 2026, down from 34 in Q4 2025.
  • Funds reported $7.01M of Kyntra Bio stock for Q1 2026, down 31% quarter-over-quarter.
  • 8 funds opened new Kyntra Bio positions in Q1 2026 and 8 closed out, a net change of 0 holders.
  • The largest Kyntra Bio buyer in Q1 2026 was Birchview Capital, an estimated $177K added.
  • The largest Kyntra Bio seller in Q1 2026 was Marshall Wace, an estimated $285K sold.

Based on aggregated 13F filings for Q1 2026.